Day: March 7, 2023

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 11:20 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at www.soleno.life. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome...

MINNEAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023. Inspire is scheduled to present at 9:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com. About Inspire Medical SystemsInspire is a medical technology company focused on the development...

CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 3:35 PM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A replay will be available on the Company’s website following the event. Institutional investors interested in meeting with management during the conference may reach out to their Barclays representative. About Solid BiosciencesSolid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs,...

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2022 after the market close on Wednesday, March 22, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.Conference Call & Webcast Details:Date: Wednesday, March 22ndTime: 4:30pm ETToll Free: 1-877-704-4453International: 1-201-389-0920 Conference ID: 13736906Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1602716&tp_key=5d40c4c9f6About LifeMDLifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care,...

HALIFAX, Nova Scotia, March 07, 2023 (GLOBE NEWSWIRE) — ELCORA ADVANCED MATERIALS CORP. (TSX.V:ERA | Frankfurt:ELM | OTCQB – ECORF) (the “Company” or “Elcora”) is pleased to announce that it has received, through its Ermazon SARL wholly owned subsidiary, a Manganese Exploitation License from the Moroccan government for its site named “Atlas Fox Deposit” in the region. This license allows Elcora to mine, extract, process and sell Manganese from its 16 km² mining concession in Morocco. The Atlas Fox Deposit had been mined until the mid-fifties when the French rule in Morocco came to an end. A representative amount of the mineral was sent to the SGS-certified African Laboratory for Mining and Environment (AFRILAB). Manganese (Mn) masses tested between 16% and 50% for an average of 34% before sorting or processing. The...

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations highlighting the Company’s proprietary Axiomer® RNA editing technology platform at upcoming scientific and industry conferences, including the 8th annual Oligonucleotide and Precision Therapeutics (OPT) Congress, March 13-14, 2023 in Boston, MA, U.S.; RNA Leaders Europe Congress, March 15-16, 2023, in Basel, Switzerland; and the bi-annual RNA Editing Gordon Research Conference (GRC), March 19-24, 2023 in Ventura, CA, U.S. Presentation and panel session at the Oligonucleotide and Precision Therapeutics (OPT) Congress Oral presentation title: Therapeutic potential of an RNA editing platform using...

Männedorf, Switzerland, March 7, 2023 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media conference call to discuss the full-year 2022 financial results on Tuesday, March 14, 2023 at 09:00 am CET. The press release with the 2022 full-year financial results and the Annual Report 2022 will be published on March 14, 2023 at 6:30 am CET. The conference call will be audio-webcast with synchronized presentation slides. A link to the webcast will be made available in the “Investor Relations” section of Tecan’s website www.tecan.com immediately prior to the event. Interested parties can also listen to the conference by phone.The dial-in numbers for the call are as follows:Participants from Europe: +41 58 310 50 00 or +44 207 107 0613 (UK)Participants from the U.S.: +1 631 570 5613 Participants should...

eQ Plc Stock Exchange Release7 February 2023, at 3:00 pm Lotta Kopra, who has been on the Board of Directors of eQ Plc since 2019, has informed the company that she is moving to McKinsey & Company’s service and for this reason, contrary to her previous announcement, is no longer available as a member of eQ Plc’s Board of Directors after the 2023 Annual General Meeting. eQ Plc will update the Notice of the Annual General Meeting and the meeting agenda on the website https://www.eq.fi/en/about-eq-group/hallinnointi/yhtiokokoukset accordingly. Helsinki, 7 March 2023 eQ Plc Mikko KoskimiesCEO Additional information: Mikko Koskimies, CEO, tel. +358 9 6817 8799 Distribution: Nasdaq Helsinki, www.eQ.fi eQ Group is a Finnish group of companies specialising in asset management and corporate finance business. eQ Asset Management...

VANCOUVER, British Columbia and LAS VEGAS, March 07, 2023 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (“Hydreight” or the “Company“) (TSXV: NURS)(FSE: SO6)(OTCQB: HYDTF) an on-demand home healthcare and wellness platform, is pleased to announce that it has onboarded new service providers in over 612 cities in the past 12 months. Hydreight is available throughout the U.S., with California, Georgia, Texas, and New York showing the strongest growth in the past year. Its unique regulatory framework makes it possible for nurses and other licensed health and wellness professionals to deliver care independently, outside of traditional medical facilities. Patients can use the app to book home health and wellness services, ranging from IV infusions to diagnostic tests, personal care, aesthetic services, and more....

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) — Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB). Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets. “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs,” said Dr. Ivan Cornella, Chief Scientific Officer of Covant. “I am thrilled to welcome our new Scientific Advisory Board members. I believe that each of them is positioned to contribute significantly to Covant’s success in bringing novel covalent therapeutics to patients.” The founding members of Covant’s SAB are:Dr. Alan D’Andrea...